- Home
- GILD vs APH Comparison
GILD vs APH Comparison
Compare GILD & APH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- APH
- Stock Information
- Founded
- GILD 1987
- APH 1932
- Country
- GILD United States
- APH United States
- Employees
- GILD N/A
- APH N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- APH Electrical Products
- Sector
- GILD Health Care
- APH Technology
- Exchange
- GILD Nasdaq
- APH Nasdaq
- Market Cap
- GILD 145.4B
- APH 167.3B
- IPO Year
- GILD 1992
- APH 1991
- Fundamental
- Price
- GILD $122.58
- APH $138.87
- Analyst Decision
- GILD Buy
- APH Strong Buy
- Analyst Count
- GILD 22
- APH 11
- Target Price
- GILD $120.90
- APH $140.64
- AVG Volume (30 Days)
- GILD 6.9M
- APH 8.3M
- Earning Date
- GILD 10-30-2025
- APH 10-22-2025
- Dividend Yield
- GILD 2.58%
- APH 0.72%
- EPS Growth
- GILD 6514.05
- APH 72.40
- EPS
- GILD 6.42
- APH 3.00
- Revenue
- GILD $29,087,000,000.00
- APH $20,973,500,000.00
- Revenue This Year
- GILD $3.05
- APH $44.14
- Revenue Next Year
- GILD $3.29
- APH $12.93
- P/E Ratio
- GILD $19.09
- APH $46.29
- Revenue Growth
- GILD 2.79
- APH 47.36
- 52 Week Low
- GILD $86.08
- APH $56.45
- 52 Week High
- GILD $124.61
- APH $142.50
- Technical
- Relative Strength Index (RSI)
- GILD 61.86
- APH 64.49
- Support Level
- GILD $114.02
- APH $135.86
- Resistance Level
- GILD $121.58
- APH $142.50
- Average True Range (ATR)
- GILD 3.17
- APH 4.00
- MACD
- GILD 0.07
- APH 0.38
- Stochastic Oscillator
- GILD 80.83
- APH 79.88
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About APH Amphenol Corporation
Amphenol is a global supplier of connectors, sensors, and interconnect systems. It holds the second-largest connector market share globally and sells into the automotive, broadband, commercial air, industrial, IT and data communications, military, mobile devices, and mobile networks end markets. Amphenol is diversified geographically, with operations in 40 countries.